NASDAQ:SABS

SAB Biotherapeutics (SABS) Stock Forecast, Price & News

$0.91

+0.02 (+2.25%)

(As of 06/1/2023 ET)

Compare

Today's Range: $0.88
▼
$0.93
50-Day Range: $0.38
▼
$1.09
52-Week Range: $0.37
▼
$2.19

Volume: 73,073 shs
Average Volume: 838,598 shs
Market Capitalization: $45.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.67

SAB Biotherapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 302.9% Upside
$3.67 Price Target
Short Interest: Healthy
1.87% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.52
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.53) to ($0.44) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

931st out of 1,980 stocks

Biological Products, Except Diagnostic Industry

135th out of 330 stocks

3.5

Analyst's Opinion

Consensus Rating
SAB Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.67, SAB Biotherapeutics has a forecasted upside of 302.9% from its current price of $0.91.
Amount of Analyst Coverage
SAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.87% of the float of SAB Biotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
SAB Biotherapeutics has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in SAB Biotherapeutics has recently increased by 28.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
SAB Biotherapeutics does not currently pay a dividend.
Dividend Growth
SAB Biotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SABS.

2.0

News and Social Media Coverage

News Sentiment
SAB Biotherapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for SAB Biotherapeutics this week, compared to 1 article on an average week.
Search Interest
Only 12 people have searched for SABS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
31.90% of the stock of SAB Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 20.94% of the stock of SAB Biotherapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($0.53) to ($0.44) per share.
Price to Book Value per Share Ratio
SAB Biotherapeutics has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About SAB Biotherapeutics (NASDAQ:SABS) Stock

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Receive SABS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SAB Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

SABS Stock News Headlines

May 30, 2023 | finance.yahoo.com

SAB Biotherapeutics to Present Novel Human IgG Platform with Positive Data and Breakthrough Therapy and Fast-Track Designations for Influenza Treatment at BIO 2023 International Convention

May 30, 2023 | americanbankingnews.com

SAB Biotherapeutics, Inc. (NASDAQ:SABS) Sees Large Growth in Short Interest

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 23, 2023 | americanbankingnews.com

FY2023 EPS Estimates for SAB Biotherapeutics, Inc. Raised by Chardan Capital (NASDAQ:SABS)

May 19, 2023 | finance.yahoo.com

SAB Biotherapeutics Presents Virtual 2023 R&D Day Portfolio Update: Breakthrough Immunotherapy Innovations

May 19, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) Boosted by Analyst

May 16, 2023 | msn.com

SAB Biotherapeutics: Q1 Earnings Insights

May 16, 2023 | finanznachrichten.de

SAB Biotherapeutics, Inc.: SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

May 16, 2023 | finance.yahoo.com

SAB Biotherapeutics Provides Company Update for Q1 2023 Financial Results

May 12, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies

May 11, 2023 | barrons.com

SAB Biotherapeutics Inc.

May 9, 2023 | marketwatch.com

SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's Groundbreaking DiversitAb(TM) Platform

May 4, 2023 | msn.com

EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials

May 3, 2023 | finance.yahoo.com

SAB Biotherapeutics to Present at Sidoti Virtual Investor Conference, May 10-11

April 29, 2023 | marketwatch.com

8-K: SAB Biotherapeutics, Inc.

April 26, 2023 | finance.yahoo.com

SAB Biotherapeutics Sees Positive Results from COVID Drug SAB-185

April 26, 2023 | msn.com

EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial

April 26, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces Positive Results from Phase 3 Trial of SAB-185 in Patients with COVID-19 at High-Risk for Severe Complications

April 22, 2023 | americanbankingnews.com

HC Wainwright Analysts Cut Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS)

April 21, 2023 | americanbankingnews.com

SAB Biotherapeutics, Inc. Forecasted to Post FY2023 Earnings of ($0.52) Per Share (NASDAQ:SABS)

April 19, 2023 | morningstar.com

SAB Biotherapeutics Shares Soar on FDA's Breakthrough Designation

April 18, 2023 | msn.com

SAB Biotherapeutics Blasts Up on Flu Treatments

April 18, 2023 | benzinga.com

Short Volatility Alert: Sab Biotherapeutics

April 18, 2023 | benzinga.com

EXCLUSIVE: SAB Biotherapeutics Secures FDA Breakthrough Therapy Tag For Its Influenza Immunotherapy

April 18, 2023 | finance.yahoo.com

SAB Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation to SAB-176 Influenza Immunotherapy

April 13, 2023 | msn.com

Why Is SAB Therapeutics Stock Trading Higher Today?

See More Headlines

SABS Price History

30 days | 90 days | 365 days | Advanced Chart

SABS Company Calendar

Last Earnings: 5/16/2023
Today: 6/01/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:SABS
CUSIP: N/A
CIK: 1833214
Web: www.bigcypressaccorp.com
Phone: 605-679-6980
Fax: N/A
Employees: 139
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.67
High Stock Price Forecast: $4.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +302.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-18,740,000.00
Net Margins: -213.54%
Pretax Margin: -214.06%
Return on Equity: -87.92%
Return on Assets: -52.78%

Debt

Debt-to-Equity Ratio: 0.17
Current Ratio: 1.10
Quick Ratio: 1.10

Sales & Book Value

Annual Sales: $23.90 million
Price / Sales: 1.92
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 1.90

Miscellaneous

Outstanding Shares: 50,400,000
Free Float: 34,321,000
Market Cap: $45.86 million
Optionable: Not Optionable
Beta: 1.41

Key Executives

Mr. Samuel J. Reich (Age 48)
Exec. Chairman
Comp: $212.58k

Dr. Eddie Joe Sullivan Ph.D. (Age 57)
Co-Founder, Pres, CEO & Director
Comp: $526.82k

Ms. Christine E. Hamilton M.B.A. (Age 67)
Co-Founder & Independent Director
Comp: $25k

Dr. Edward D. Hamilton D.V.M.
Co-Founder & Board Observer

Mr. Russell P. Beyer C.M.A. (Age 68)
M.B.A., Exec. VP & CFO

Dr. Christoph Bausch M.B.A. (Age 52)
Ph.D., Exec. VP & COO

Dr. Carlos N. Carillo Ph.D.
Sr. VP of Regulatory Affairs

Dr. Alexandra Kropotova M.B.A. (Age 51)
M.D., Exec. VP & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SABS Stock - Frequently Asked Questions

Should I buy or sell SAB Biotherapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SAB Biotherapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SABS shares.
View SABS analyst ratings or view top-rated stocks.
What is SAB Biotherapeutics' stock price forecast for 2023?: 2 Wall Street research analysts have issued 12-month price targets for SAB Biotherapeutics' stock. Their SABS share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.67 in the next year. This suggests a possible upside of 302.9% from the stock's current price.
View analysts price targets for SABS or view top-rated stocks among Wall Street analysts.
How have SABS shares performed in 2023?: SAB Biotherapeutics' stock was trading at $0.5899 at the beginning of the year. Since then, SABS shares have increased by 54.3% and is now trading at $0.91.
View the best growth stocks for 2023 here.
Are investors shorting SAB Biotherapeutics?: SAB Biotherapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 665,400 shares, an increase of 28.3% from the April 30th total of 518,600 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 1.9% of the shares of the stock are sold short.
View SAB Biotherapeutics' Short Interest.
When is SAB Biotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SABS earnings forecast.
How were SAB Biotherapeutics' earnings last quarter?: SAB Biotherapeutics, Inc. (NASDAQ:SABS) posted its quarterly earnings results on Tuesday, May, 16th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.08) by $0.07. The business earned $0.58 million during the quarter, compared to the consensus estimate of $5.56 million. SAB Biotherapeutics had a negative trailing twelve-month return on equity of 87.92% and a negative net margin of 213.54%.

What is SAB Biotherapeutics' stock symbol?: SAB Biotherapeutics trades on the NASDAQ under the ticker symbol "SABS."
Who are SAB Biotherapeutics' major shareholders?: SAB Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include First Manhattan CO. LLC. (0.55%).
View institutional ownership trends.
How do I buy shares of SAB Biotherapeutics?: Shares of SABS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is SAB Biotherapeutics' stock price today?: One share of SABS stock can currently be purchased for approximately $0.91.
How much money does SAB Biotherapeutics make?: SAB Biotherapeutics (NASDAQ:SABS) has a market capitalization of $45.86 million and generates $23.90 million in revenue each year.
How many employees does SAB Biotherapeutics have?: The company employs 139 workers across the globe.
How can I contact SAB Biotherapeutics?: SAB Biotherapeutics' mailing address is 300 W. 41ST STREET SUITE 202, MIAMI BEACH FL, 33140. The official website for the company is www.bigcypressaccorp.com. The company can be reached via phone at 605-679-6980 or via email at ir@bigcypressaccorp.com.

This page (NASDAQ:SABS) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial